Skip to main content
Tuoxin Pharmaceutical Group Co.,Ltd. logo

Tuoxin Pharmaceutical Group Co.,Ltd. — Investor Relations & Filings

Ticker · 301089 ISIN · CNE100004YC3 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 734 across all filing types
Latest filing 2022-10-12 Regulatory Filings
Country CN China
Listing Shenzhen Stock Exchange 301089

About Tuoxin Pharmaceutical Group Co.,Ltd.

https://www.tuoxinpharm.com

Tuoxin Pharmaceutical Group Co., Ltd. specializes in the research, development, production, and distribution of nucleosides and nucleotides. The company serves as a major global supplier of active pharmaceutical ingredients (APIs) and chemical intermediates. Its core product portfolio includes cytidine, inosine, guanosine, adenosine, and their various derivatives, which are essential components in the synthesis of antiviral, anti-tumor, and cardiovascular medications. Notably, the group provides key intermediates for drugs such as Ribavirin and Azvudine. Tuoxin Pharmaceutical leverages advanced synthetic biotechnology and large-scale manufacturing capabilities to support the global pharmaceutical industry. The company maintains a focus on technological innovation and quality control to ensure the stability and purity of its chemical products for diverse therapeutic applications.

Recent filings

Filing Released Lang Actions
监事会对深圳证券交易所关注函的核查意见
Regulatory Filings Classification · 95% confidence The document is a supervisory board's verification opinion responding to a regulatory inquiry (关注函) from the Shenzhen Stock Exchange regarding the company's restricted stock incentive plan. It is a formal response to a regulatory concern rather than a full report or financial statement. The document length is very short (450 characters), and it does not contain financial data or detailed report content. It is not an announcement of a report publication but a regulatory compliance response. Therefore, it fits best under Regulatory Filings (RNS), which covers miscellaneous regulatory announcements and compliance documents that do not fit other categories.
2022-10-12 Chinese
监事会关于2022年限制性股票激励计划首次授予激励对象名单的公示情况说明及核查意见
Regulatory Filings Classification · 95% confidence The document is a public announcement by the supervisory board regarding the first grant of a 2022 restricted stock incentive plan and the verification of the list of incentive recipients. It includes details about the disclosure, compliance with regulatory requirements, and confirmation that the incentive recipients meet legal and regulatory conditions. The document does not contain financial statements or detailed financial data but is a formal announcement related to a stock incentive plan and its compliance verification. It is not an annual report, earnings release, or management report, nor is it a proxy solicitation or remuneration report. It fits best as a Regulatory Filing (RNS) because it is a compliance-related announcement that does not fit other specific categories and is relatively short (1608 characters).
2022-10-10 Chinese
关于召开2022年第五次临时股东大会的通知
AGM Information Classification · 95% confidence The document is a detailed notice about the convening of the 2022 fifth extraordinary general meeting (临时股东大会) of Xinxiang Tuoxin Pharmaceutical Co., Ltd. It includes information about the meeting date, voting procedures (both onsite and online), registration details, agenda items, and proxy voting instructions. The document does not contain financial statements or results but is a formal announcement to shareholders about the meeting and how to participate and vote on specific proposals, including a restricted stock incentive plan. This matches the description of a shareholder meeting notice rather than the meeting materials or results. Therefore, the document is best classified as AGM Information (AGM-R), which covers presentations and materials shared during the Annual General Meeting or similar shareholder meetings.
2022-09-28 Chinese
北京市康达律师事务所关于新乡拓新药业股份有限公司2022年限制性股票激励计划的法律意见书
Remuneration Information Classification · 95% confidence The document is a detailed legal opinion letter from a law firm regarding a 2022 restricted stock incentive plan for a company named 新乡拓新药业股份有限公司. It extensively discusses the legal compliance, procedures, eligibility, and terms of the stock incentive plan, including board and shareholder approvals, stock quantities, pricing, vesting conditions, and related legal regulations. The document is not a financial report, earnings release, or regulatory announcement but a legal opinion on a specific corporate governance and compensation matter related to stock incentives. This type of document fits best under the category of Remuneration Information (DEF 14A), which covers reports detailing compensation plans for executives and directors, including stock incentive plans. The document is substantive and lengthy (15,000 characters), not a brief announcement or certification, so it is not RNS or RPA. Therefore, the classification is DEF 14A with high confidence.
2022-09-28 Chinese
2022年限制性股票激励计划首次授予激励对象名单
Remuneration Information Classification · 95% confidence The document is titled as a list of recipients for a 2022 restricted stock incentive plan initial grant by the company 新乡拓新药业股份有限公司. It details the allocation of restricted stock to board members, senior management, and core personnel, including quantities and percentages. This type of document is related to executive compensation and share-based incentives. It is not a full annual report, earnings release, or financial statement. It is not a proxy solicitation or voting result announcement. It is specifically about remuneration through stock incentives, which aligns with the Remuneration Information category (DEF 14A). The document length is short (1665 characters), and it contains detailed allocation data rather than just an announcement or a link to a report, so it is not a report publication announcement or regulatory filing. Therefore, the best classification is Remuneration Information (DEF 14A).
2022-09-28 Chinese
第四届监事会第十一次会议决议公告
Board/Management Information Classification · 95% confidence The document is a formal announcement of resolutions passed at the 11th meeting of the 4th Supervisory Board of Xinxiang Tuoxin Pharmaceutical Co., Ltd. It details the meeting's convening, the approval of a 2022 restricted stock incentive plan draft, its implementation assessment methods, and the initial list of incentive recipients. The content focuses on governance decisions and approvals related to stock incentive plans, with voting results and compliance statements. There are no financial statements, earnings data, or audit information. The document is a meeting resolution announcement by the supervisory board, which fits best under Board/Management Information (MANG) as it relates to governance and management decisions rather than a full report or regulatory filing. The document length is short and does not indicate it is an announcement of a report publication or a regulatory filing. Therefore, the classification is MANG with high confidence.
2022-09-28 Chinese

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.